[Table_scodeMsg1] 公司研究丨深度报告丨京新药业（002020.SZ） [Table_Title] 传统业务稳健，创新打开成长空间 %% %% %% %% research.95579.com 1 丨证券研究报告丨 报告要点 [Table_Summary] 京新药业成立于 1990 年，2004 年在深交所上市，业务覆盖中枢神经系统（CNS）、心血管（CVD） 及消化道等领域，已形成原料药-制剂-器械一体化布局。公司在仿制药领域深耕多年，核心品 种受益集采放量，业务基础稳健。近年来，公司加快创新转型，CNS 领域地达西尼已实现商业 化并进入医保；CVD 领域 JX2201 切入全球瞩目的 Lp(a)降脂新机制，具备 BD 出海潜力；此 外还有潜力巨大的精神分裂症管线 JX11502MA、帕金森管线 JX2105。我们认为，公司凭借传 统业务筑基，创新药商业化兑现，叠加部分管线 BD 预期，公司有望进入快速发展新阶段。 分析师及联系人 [Table_Author] 彭英骐 刘长洪 SAC：S0490524030005 SAC：S0490525070007 SFC：BUZ392 请阅读最后评级说明 ...

Core Viewpoint - Jingxin Pharmaceutical is a well-known domestic pharmaceutical company specializing in the fields of mental health and cardiovascular diseases, with a comprehensive business model covering chemical preparations, traditional Chinese medicine, biological preparations, chemical raw materials, and medical devices [1] Business Performance - In Q3 2025, Jingxin Pharmaceutical reported a revenue of 3.048 billion yuan, ranking 24th among 110 companies in the industry, with the top company, East China Pharmaceutical, generating 32.664 billion yuan [2] - The net profit for the same period was 581 million yuan, placing the company 16th in the industry, while the leading company, Hengrui Medicine, achieved a net profit of 5.76 billion yuan [2] Financial Ratios - As of Q3 2025, Jingxin Pharmaceutical's debt-to-asset ratio was 28.74%, down from 31.73% year-on-year, and below the industry average of 35.26%, indicating strong solvency [3] - The gross profit margin for the same period was 50.07%, slightly down from 51.11% year-on-year, and lower than the industry average of 57.17% [3] Executive Compensation - The chairman and president, Lv Gang, received a salary of 1.4836 million yuan in 2024, a decrease of 151,900 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 13.08% to 22,300, while the average number of circulating A-shares held per shareholder increased by 15.05% to 32,400 [5] - The top ten circulating shareholders included Hong Kong Central Clearing Limited, which held 7.4588 million shares, a decrease of 2.1904 million shares from the previous period [5] Future Outlook - The company is focusing on the mental health and cardiovascular sectors, with expectations for double-digit growth in overall performance, driven by the launch of innovative drugs [5] - Projected revenues for 2025, 2026, and 2027 are 4.565 billion, 5.124 billion, and 5.770 billion yuan, respectively, with net profits of 791 million, 905 million, and 1.025 billion yuan [5] - Guotai Junan Securities noted that the company’s non-recurring profit exceeded expectations, with significant growth in foreign trade revenue and advancements in its innovative drug pipeline [6]

Core Insights - The insomnia medication market in China is experiencing a resurgence with new products being approved after a long hiatus, indicating increasing competition among both new and existing drugs [2][4][5] - The market size for insomnia medications in China was 12.28 billion yuan in 2021, projected to reach 15.12 billion yuan by 2025 and 21.19 billion yuan by 2030, highlighting significant growth potential [3][7] Company Developments - Xiansheng Pharmaceutical plans to invest 30 million yuan over the next three years in an open research initiative for new insomnia drugs, inviting external participants to collaborate on research projects [2][6] - The newly approved drug Dali Leisheng by Xiansheng Pharmaceutical is a dual orexin receptor antagonist, marking a significant advancement in insomnia treatment options [5][6] Industry Trends - The prevalence of insomnia in China is high, with an estimated 38.2% of adults affected, leading to increased focus on sleep health and the demand for effective treatments [3][7] - The insomnia drug market has evolved through four generations, with the latest generation focusing on orexin receptor antagonists, which offer a novel mechanism of action compared to traditional sedatives [3][4] Competitive Landscape - The approval of new insomnia medications, such as Dali Leisheng and Jiyin Pharmaceutical's innovative drug, is intensifying competition in the market, with companies actively promoting their products [5][7] - The market is currently dominated by second-generation drugs like Midazolam, while newer fourth-generation drugs are still in the early stages of commercialization [5][6]

Core Insights - The Chinese innovative drug sector has become a hot area in the capital market this year, driven by the real demand for high-quality innovative drugs from domestic patients, which is seen as the core driver for industry recovery [1] Group 1: Market Performance - In the first half of this year, 21 innovative drug companies listed on A-shares achieved a revenue of 28.69 billion yuan, a year-on-year increase of approximately 42%, while 32 innovative drug companies listed on H-shares reported a revenue of 42.13 billion yuan, a year-on-year increase of about 10% [2] - Leading companies have shown particularly strong performance, with Heng Rui Medicine's innovative drug sales revenue reaching 7.57 billion yuan, a year-on-year increase of approximately 14.5% [2] - Innovative drugs from Bai Jie Shen Zhou, such as Bai Yue Ze and Bai Ze An, reported sales of 1.192 billion yuan and 2.643 billion yuan respectively, with year-on-year growth rates of 36.5% and 20.6% [2] Group 2: Policy and Market Dynamics - The Chinese innovative drug market is entering a dual development cycle with domestic medical insurance and overseas markets, leading to a gradual path to profitability for companies [2] - Since its establishment in 2018, the National Medical Insurance Bureau has included 149 innovative drugs in the medical insurance catalog through seven rounds of adjustments, significantly optimizing the clinical medication structure [3] - By May 2025, the medical insurance fund is expected to pay a cumulative 410 billion yuan for negotiated drugs, driving related drug sales to exceed 600 billion yuan [3] Group 3: Future Outlook - The innovative drug market in China is projected to reach a scale of 162 billion yuan by 2024, with medical insurance payments accounting for approximately 43.8% [4] - The commercial success of innovative drugs is seen as a starting point for higher-level research and development, with many companies increasing their R&D investments despite revenue growth [4] - China currently holds a 30% share in global drug research and development, with 1,775 first-in-class drug pipelines, representing 19% of the global total [4]

Investment Rating - The report maintains an "Accumulate" rating for the company [6][13]. Core Views - The company's Q2 2025 non-GAAP profit exceeded expectations, driven by the volume increase of Didasun and the gradual advancement of its innovative pipeline, indicating a positive outlook for its transformation into innovation [2][13]. Financial Summary - Total revenue for H1 2025 was 2.017 billion yuan, a decrease of 6.2% year-on-year, while net profit attributable to the parent company was 388 million yuan, down 3.5%. The non-GAAP net profit was 360 million yuan, an increase of 7.8%. The gross margin was 49.6%, down 2.0 percentage points [13]. - For Q2 2025, the single-quarter revenue was 1.06 billion yuan, a decrease of 2.6%, with a net profit of 225 million yuan, down 2.7%. The non-GAAP net profit was 214 million yuan, an increase of 20.4%, and the gross margin was 51.2%, down 0.03 percentage points [13]. - The company adjusted its EPS forecasts for 2025-2026 to 0.94 and 1.09 yuan respectively, with a new forecast for 2027 at 1.30 yuan. The target price was raised to 27.25 yuan based on a 25x PE for 2026 [13]. Business Performance - The main business remains stable, with the finished drug revenue for H1 2025 at 1.175 billion yuan, down 9.7%. However, foreign trade revenue grew over 30.1%. The innovative drug Didasun had its first year of insurance coverage, generating 55 million yuan in revenue during the reporting period [13]. - The raw material drug segment reported revenue of 453 million yuan, down 9.6%, while the medical device segment saw revenue of 349 million yuan, an increase of 12.0% [13]. Innovation Pipeline - The innovative pipeline is expected to continue catalyzing growth, with several drugs in various stages of clinical trials, including JX11502MA for schizophrenia and JX2201 for cardiovascular issues [13].

Investment Rating - The report maintains a "Recommended" investment rating for Jingxin Pharmaceutical (002020.SZ) [1][8][10] Core Views - The company is expected to see continued growth in its innovative pipeline, particularly with the ongoing expansion of its first-class innovative drug, Didasinib [7][8] - The company reported a revenue of 2.017 billion yuan for H1 2025, a year-on-year decrease of 6.20%, while the net profit attributable to shareholders was 388 million yuan, down 3.54% year-on-year [4][7] - The report anticipates that the company will achieve revenues of 4.724 billion yuan, 5.357 billion yuan, and 6.092 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 13.6%, 13.4%, and 13.7% [6][8] Financial Performance - In H1 2025, the company's revenue from finished drugs was 1.175 billion yuan, down 9.68% year-on-year, while revenue from medical devices increased by 12.01% to 349 million yuan [7] - The gross margin for H1 2025 was 49.57%, a decrease of 2.00 percentage points year-on-year, while the net margin increased by 0.57 percentage points to 19.45% [7] - The company expects to maintain its profit forecasts, projecting net profits of 829 million yuan, 947 million yuan, and 1.102 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 16.4%, 14.3%, and 16.4% [8] Innovative Pipeline - The innovative drug Didasinib has seen significant growth, generating 55 million yuan in revenue in H1 2025, with over 1,500 hospitals now covered [7][8] - The company has a rich pipeline of drugs under development, including a first-class innovative drug for schizophrenia that has completed Phase II clinical trials and a new drug for cardiovascular diseases that is progressing through Phase I trials [7][8]

Core Insights - The company reported a revenue of 2.017 billion yuan for H1 2025, a decrease of 6.2% year-on-year, and a net profit attributable to shareholders of 388 million yuan, down 3.54% year-on-year [1] - The company experienced a decline in revenue from finished drugs and raw materials, while the medical device segment showed growth [2] - The innovative drug, Didasinib capsules, generated over 55 million yuan in revenue, indicating successful market penetration and collaboration with healthcare institutions [3] Financial Performance - H1 2025 finished drug revenue was 1.175 billion yuan (down 9.68% YoY), raw material drug revenue was 453 million yuan (down 9.59% YoY), and medical device revenue was 349 million yuan (up 12.01% YoY) [2] - The company's non-GAAP net profit increased by 7.78% YoY, driven by a reduction in sales and management expense ratios, leading to a non-GAAP net profit margin of approximately 17.87% [2] Innovation and Development - The company is focusing on the commercialization of its innovative drug Didasinib, having expanded its hospital coverage to over 1,500 institutions [3] - The company is advancing its pipeline in various therapeutic areas, including mental health, cardiovascular, and digestive diseases, with significant progress in clinical trials [4] Revenue Forecast - Projected revenues for 2025-2027 are 4.413 billion yuan, 4.849 billion yuan, and 5.361 billion yuan, with year-on-year growth rates of approximately 6%, 10%, and 11% respectively [4] - Expected net profits for the same period are 802 million yuan, 909 million yuan, and 1.045 billion yuan, with corresponding growth rates of about 13%, 13%, and 15% [4]

Investment Rating - The investment rating for Jingxin Pharmaceutical (002020) is not explicitly stated in the provided content, but the report indicates a focus on growth and innovation in the pharmaceutical sector [1]. Core Insights - The report highlights that Jingxin Pharmaceutical's revenue for H1 2025 was 2.017 billion yuan, a decrease of 6.2% year-on-year, while the net profit attributable to the parent company was 388 million yuan, down 3.54% year-on-year. However, the net profit excluding non-recurring items increased by 7.78% to 360 million yuan [2][4]. - The company is experiencing short-term revenue pressure, particularly in finished drug sales, which fell by 9.68% to 1.175 billion yuan due to centralized procurement pressures. However, the medical device segment grew by 12.01% to 349 million yuan, indicating a robust performance in that area [4]. - The innovative drug, Didasini capsule, generated over 50 million yuan in revenue, demonstrating the company's ability to commercialize its innovative pipeline effectively [4]. Summary by Sections Financial Performance - In H1 2025, the company achieved total revenue of 2.017 billion yuan, with a net profit of 388 million yuan. The second quarter alone contributed 1.06 billion yuan in revenue, reflecting a 2.64% decline year-on-year [2][4]. - The gross profit margin for 2025 is projected to remain stable around 50%, with net profit growth expected to recover in the following years [6]. Revenue Breakdown - Finished drug revenue decreased to 1.175 billion yuan, raw material drug revenue fell to 453 million yuan, while medical device revenue increased to 349 million yuan [4]. - The company has expanded its market access significantly, with over 1,500 hospitals covered, enhancing the availability of its products [4]. Future Projections - Revenue is expected to grow to 4.413 billion yuan in 2025, with a compound annual growth rate (CAGR) of approximately 6% from 2025 to 2027. Net profit is projected to reach 802 million yuan in 2025, with a growth rate of 13% [7]. - The report emphasizes the potential of the JX2201 capsule in the cardiovascular disease treatment space, with ongoing clinical trials and significant market interest [5][7].

Core Viewpoint - The company reported a decline in revenue for the first half of 2025, with a focus on the commercialization progress of its core innovative drug, Didasinib, which has shown initial market penetration success [4][5]. Financial Performance - The company achieved a revenue of 2.017 billion yuan in the first half of 2025, a year-on-year decrease of 6.20% - Finished drug revenue was 1.175 billion yuan, down 9.68% - Raw material drug revenue was 453 million yuan, down 9.59% - Medical device revenue was 349 million yuan, up 12.01% - Net profit attributable to the parent company was 388 million yuan, down 3.54% - Deducted net profit attributable to the parent company was 360 million yuan, up 7.78% - Operating cash flow was 393 million yuan, down 17.48% - Basic EPS was 0.46 yuan [4]. Commercialization Progress - The core innovative drug Didasinib has made significant strides in commercialization, having been included in the National Basic Medical Insurance Drug List as of November 2024 - As of June 30, 2025, over 400 key medical institutions have been added to the access list, with a total of over 1,500 hospitals covered - The product generated revenue of 55 million yuan in the first half of 2025, indicating initial effects of insurance reimbursement [5]. R&D Pipeline Advancement - In the field of psychiatric disorders, the self-developed innovative drug JX11502 capsule has completed Phase II clinical trials, and the application for marketing authorization for Calirizine capsule has been submitted to the National Medical Products Administration - In cardiovascular disease, the pipeline continues to improve with ongoing Phase I clinical trials for a new drug targeting LP(a) mechanism and the submission of a marketing application for a drug treating high cholesterol - In digestive diseases, the modified traditional Chinese medicine for ulcerative colitis has completed Phase II clinical trials, supporting the design and implementation of Phase III trials [6].

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Insights - The commercialization of the core innovative drug, Dazisini, has achieved significant progress, with over 1,500 hospitals covered and a revenue of 55 million yuan in H1 2025 [2][4] - The company has seen a decline in revenue due to price reductions from centralized procurement policies, leading to a downward adjustment in net profit forecasts for 2025-2027 [4] Financial Performance Summary - In H1 2025, the company reported total revenue of 2.017 billion yuan, a decrease of 6.20% year-on-year, with finished drug revenue at 1.175 billion yuan, down 9.68% [1] - The net profit attributable to the parent company was 388 million yuan, a decline of 3.54% year-on-year, while the non-recurring net profit increased by 7.78% to 360 million yuan [1] - The operating cash flow was 393 million yuan, down 17.48% year-on-year, with an EPS of 0.46 yuan [1] Revenue and Profit Forecast - The revenue forecast for 2025 is adjusted to 4.1 billion yuan, with net profit estimates revised to 788 million yuan, reflecting a decrease of 13% from previous estimates [4] - The company is expected to see a gradual recovery in revenue growth, with projections of 4.58 billion yuan in 2026 and 5.068 billion yuan in 2027 [10] R&D Pipeline Progress - The company is advancing its R&D pipeline in the fields of mental health, cardiovascular, and digestive diseases, with several products in various stages of clinical trials [3][9]